Rubius reports $39.4M loss in Q2, heralds progress

PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted share. Rubius posted operating expenses, including research and development expenditures, of $41.3 million. The Cambridge, Mass.-headquartered company, which specializes in allogenic cellular therapies for several diseases and across multiple therapeutic areas,…

Want More?

Subscribe or register with Providence Business News to keep reading.

for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -